In the face of increasing cancer incidence, researchers have targeted the IGF axis for therapeutic intervention due to its role in cancer.Three main approaches are used to target IGFs, including IGF-1R monoclonal antibodies, IGF-1R tyrosine kinase inhibitors (TKIs) and IGF-1/-2 blocking monoclonal antibodies. The gene discussed is IGF1R; the disease is cancer.